A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500706-18-01

Enrollment

Registered

2023-06-26

Start date

2023-09-11

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza prophylaxis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Norway

None listed

Source: EU CTIS · Data processed: Feb 4, 2026